The Company announced its fourth quarter and full year 2017 financial results.
The Company plans on attending the Cowen Health Care Conference on Wednesday, March 14 at 10:40 a.m. ET in Boston and the Barclays Global Healthcare Conference on Thursday, March 15 in Miami.
Veterinarians stand at both the front line of medicine and the fore front of medical knowledge. Aratana Therapeutics will be at a number of veterinary conferences in the coming months to meet veterinarians interested in learning about the scientific advances we want to bring to pet health.
Aratana Therapeutics is sponsoring two nationwide clinical trials.
June 27, 2013, Aratana filed its initial public offering, validating our unique model and approach to bringing advances in human medical science to pets.
The Company will provide an overview of its business at the Jefferies Global Healthcare Conference and the William Blair Annual Growth Stock Conference.
Aratana Therapeutics – a new kind of animal health company – made their veterinary symposium debut at the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum.
The Company will provide an overview of its business at the Craig-Hallum Institutional Investor Conference and the Stifel Dental & Veterinary Conference.
The Company announced its first quarter 2014 financial results and plans to host a conference call May 13, 2014 at 4:45 p.m. ET.
The Company announced the initiation of the pivotal field effectiveness study for AT-001 (grapiprant), the company’s innovative drug for treating pain in dogs with osteoarthritis.
The Company will host a conference call and live audio webcast on Tuesday, May 13, 2014 at 4:45 p.m. ET to discuss its financial results for the quarter ended March 31, 2014.
The Company announced its presentation plans for the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum to be held June 4-7, 2014 in Nashville.
The Company announced the appointment of former Theravance executive David L. Brinkley to its Board of Directors.
The Company announced a global licensing agreement for Advaxis’ ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer.
The Company announced its fourth quarter and full year 2013 financial results and plans to host a conference call on March 13, 2014 at 8 a.m. ET.
The Company will host a conference call and live audio webcast on Thursday, March 13, 2014 at 8:00 a.m. ET to discuss its financial results for the quarter ended December 31, 2013.
The Company announced that it will present at the Barclays Global Healthcare Conference to be held March 11-13, 2014, in Miami, Florida and also at the Jefferies Animal Health Day on March 27, 2014 in New York City.
The Company announced the addition of Laura Brege, President and Chief Executive Office of Nodality, Inc., and Merilee Raines, former Executive Vice President and Chief Financial Officer of IDEXX Laboratories, to its Board of Directors.